

# SENATE CHAMBER

STATE OF OKLAHOMA

DISPOSITION

☒ FLOOR AMENDMENT

No. 1

☐ COMMITTEE AMENDMENT


(Date)


I move to amend Senate Bill No. 993, by substituting the attached floor substitute (Request # 1843) for the title, enacting clause and entire body of the measure.


Submitted by:


  
Senator Collihare

I hereby grant permission for the floor substitute to be adopted.


  
Senator Coleman, Chair (required)


  
Senator Alford

  
Senator Brooks


  
Senator Grellner


  
Senator Guthrie


  
Senator Mann


  
Senator Pugh

  
Senator Reinhardt

  
Senator Standridge

  
Senator Weaver

  
Senator Paxton, President Pro Tempore

  
Senator Daniels, Majority Floor Leader

Note: Business and Insurance committee majority requires six (6) members' signatures.

Gollihare-CAD-FS-SB993

3/12/2025 1:56 PM

(Floor Amendments Only)

Date and Time Filed: 3/18/25 2:01pm gd

☐ Untimely

☐ Amendment Cycle Extended

☐ Secondary Amendment

STATE OF OKLAHOMA

1st Session of the 60th Legislature (2025)

FLOOR SUBSTITUTE  
FOR

SENATE BILL NO. 993

By: Gollihare and Jech of the  
Senate

and

Stinson of the House

FLOOR SUBSTITUTE

An Act relating to pharmacy benefits managers;  
amending 59 O.S. 2021, Sections 356.1, 356.2, 356.3,  
as amended by Sections 1, 2, and 3, Chapter 332,  
O.S.L. 2024, and 356.4 (59 O.S. Supp. 2024, Sections  
356.1, 356.2, and 356.3), which relate to  
definitions, pharmacy audit requirements, appeals  
process, and prohibited extrapolation audit;  
modifying notice contents; prohibiting assessment of  
certain fines under certain circumstances; expanding  
certain claim limits; establishing requirements for  
preliminary audit findings reports; requiring  
provision of certain final audit results within a  
certain time period; updating statutory reference;  
requiring certain notification to Attorney General in  
certain circumstances; expanding requirement for  
initiation of certain audit; lengthening time period  
for certain preliminary report; allowing certain  
extension request; shortening certain time period for  
certain final report; establishing requirements for  
audit findings report; modifying definition; defining  
terms; requiring certain tolling in certain declared  
disaster; providing certain exceptions; amending 59  
O.S. 2021, Sections 357, 358, and 360, as amended by  
Sections 4, 5, and 6, Chapter 332, O.S.L. 2024 (59  
O.S. Supp. 2024, Sections 357, 358, and 360), which  
relate to definitions, pharmacy benefits management  
licensure, and pharmacy benefits manager contractual

1 duties; modifying notice contents; defining terms;  
2 updating statutory references; requiring certain time  
3 period of tolling in certain declared disaster;  
4 requiring certain documented proof by certain  
5 pharmacy benefits managers; establishing certain  
6 denial for certain appeals; prohibiting certain  
7 collection of additional monies by certain pharmacy  
8 benefits managers; establishing certain filing period  
9 after lifting of disaster declaration; prohibiting  
10 certain denials; updating statutory language;  
11 providing for codification; and declaring an  
12 emergency.

13 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

14 SECTION 1. AMENDATORY 59 O.S. 2021, Section 356.1, as  
15 amended by Section 1, Chapter 332, O.S.L. 2024 (59 O.S. Supp. 2024,  
16 Section 356.1), is amended to read as follows:

17 Section 356.1. A. For purposes of the Pharmacy Audit Integrity  
18 Act, ~~"pharmacy benefits manager":~~

19 1. "Audit" means any review, inspection, or analysis conducted  
20 by a pharmacy benefits manager (PBM) or its representative of a  
21 pharmacy's records, practices, or compliance with contractual  
22 obligations;

23 2. "Disaster declaration" and "declared disaster" mean a  
24 declaration issued by the Governor or the President of the United  
States for an event that qualifies as a disaster including, but not  
limited to, a flood, tornado, earthquake, wildfire, terrorist  
attack, or other catastrophic event; and

1        3. "Pharmacy benefits manager" or "PBM" shall have the same  
2 meaning as in Section 6960 of Title 36 of the Oklahoma Statutes.

3        B. The purpose of the Pharmacy Audit Integrity Act is to  
4 establish minimum and uniform standards and criteria for the audit  
5 of pharmacy records by or on behalf of certain entities.

6        C. The Pharmacy Audit Integrity Act shall apply to any audit of  
7 the records of a pharmacy conducted by a managed care company,  
8 nonprofit hospital, medical service organization, insurance company,  
9 third-party payor, pharmacy benefits manager, a health program  
10 administered by a department of this state, or any entity that  
11 represents these companies, groups, or departments.

12        D. The Attorney General may promulgate rules to implement the  
13 provisions of the Pharmacy Audit Integrity Act.

14        SECTION 2.        AMENDATORY        59 O.S. 2021, Section 356.2, as  
15 amended by Section 2, Chapter 332, O.S.L. 2024 (59 O.S. Supp. 2024,  
16 Section 356.2), is amended to read as follows:

17        Section 356.2. A. The entity conducting an audit of a pharmacy  
18 shall:

19        1. Identify and specifically describe the audit and appeal  
20 procedures in the pharmacy contract. Prescription claim  
21 documentation and ~~record-keeping~~ recordkeeping requirements shall  
22 not exceed the requirements set forth by the Oklahoma Pharmacy Act  
23 or other applicable state or federal laws or regulations;

1        2. Give the pharmacy written notice by certified letter to the  
2 pharmacy and the pharmacy's contracting agent, including  
3 identification of specific prescription numbers ~~and~~, fill dates,  
4 drug names, and National Drug Code (NDC) numbers to be audited, at  
5 least fourteen (14) calendar days prior to conducting the audit,  
6 including, but not limited to, an on-site audit, a desk audit, or a  
7 wholesale purchase audit, request for documentation related to the  
8 dispensing of a prescription drug, or any reimbursed activity by a  
9 pharmacy provider; provided, however, that wholesale purchase audits  
10 shall require a minimum of thirty (30) calendar days' written  
11 notice. For an on-site audit, the audit date shall be the date the  
12 on-site audit occurs. For all other audit types, the audit date  
13 shall be the date the pharmacy provides the documentation requested  
14 in the audit notice. The pharmacy shall have the opportunity to  
15 reschedule the audit no more than seven (7) calendar days from the  
16 date designated on the original audit notification;

17        3. Not interfere with the delivery of pharmacist services to a  
18 patient and shall utilize every reasonable effort to minimize  
19 inconvenience and disruption to pharmacy operations during the audit  
20 process;

21        4. Conduct any audit involving clinical or professional  
22 judgment by means of or in consultation with a licensed pharmacist;

23        5. Not consider as fraud any clerical or ~~record-keeping~~  
24 recordkeeping error, such as a typographical error, scrivener's

1 error or computer error, including, but not limited to, a  
2 miscalculated day supply, incorrectly billed prescription written  
3 date or prescription origin code, and such errors shall not be  
4 subject to recoupment. The pharmacy shall have the right to submit  
5 amended claims electronically to correct clerical or ~~record-keeping~~  
6 recordkeeping errors in lieu of recoupment. To the extent that an  
7 audit results in the identification of any clerical or ~~record-~~  
8 ~~keeping~~ recordkeeping errors such as typographical errors,  
9 scrivener's errors or computer errors in a required document or  
10 record, the pharmacy shall not be subject to recoupment of funds by  
11 the pharmacy benefits manager unless the pharmacy benefits manager  
12 can provide proof of intent to commit fraud. A person shall not be  
13 subject to criminal penalties for errors provided for in this  
14 paragraph without proof of intent to commit fraud;

15 6. Permit a pharmacy to use the records of a hospital,  
16 physician, or other authorized practitioner of the healing arts for  
17 drugs or medicinal supplies written or transmitted by any means of  
18 communication for purposes of validating the pharmacy record with  
19 respect to orders or refills of a legend or narcotic drug;

20 7. Not include the dispensing fee amount or the actual invoice  
21 cost of the prescription dispensed in a finding of an audit  
22 recoupment unless a prescription was not actually dispensed or a  
23 physician denied authorization of a dispensing order;

1        8. Audit each pharmacy under identical standards, regularity  
2 and parameters as other similarly situated pharmacies and all  
3 pharmacies owned or managed by the pharmacy benefits manager  
4 conducting or having conducted the audit;

5        9. Not exceed one (1) year from the date the claim was  
6 submitted to or adjudicated by a managed care company, nonprofit  
7 hospital or medical service organization, insurance company, third-  
8 party payor, pharmacy benefits manager, a health program  
9 administered by a department of this state, or any entity that  
10 represents the companies, groups, or departments for the period  
11 covered by an audit;

12        10. Not schedule or initiate an audit during the first seven  
13 (7) calendar days of any month unless otherwise consented to by the  
14 pharmacy;

15        11. Disclose to any plan sponsor whose claims were included in  
16 the audit any money recouped in the audit;

17        12. Not require pharmacists to break open packaging labeled  
18 "for single-patient-use only". Packaging labeled "for single-  
19 patient-use only" shall be deemed to be the smallest package size  
20 available; ~~and~~

21        13. Upon recoupment of funds from a pharmacy, refund first to  
22 the patient the portion of the recovered funds that were originally  
23 paid by the patient, provided such funds were part of the  
24 recoupment; and

1        14. Not assess a fine, penalty, or any other financial  
2        requirement on the pharmacy or pharmacist for any prescription  
3        audited unless there is a valid recoupment under the Pharmacy Audit  
4        Integrity Act.

5        B. 1. Any entity that conducts wholesale purchase review  
6        during an audit of a pharmacist or pharmacy shall not require the  
7        pharmacist or pharmacy to provide a full dispensing report.

8        Wholesaler invoice reviews shall be limited to verification of  
9        purchase inventory specific to the pharmacy claims paid by the  
10       health benefits plan or pharmacy benefits manager conducting the  
11       audit.

12       2. Any entity conducting an audit shall not identify or label a  
13       prescription claim as an audit discrepancy when:

14           a. the National Drug Code for the dispensed drug is in a  
15           quantity that is a subunit or multiple of the drug  
16           purchased by the pharmacist or pharmacy as supported  
17           by a wholesale invoice,

18           b. the pharmacist or pharmacy dispensed the correct  
19           quantity of the drug according to the prescription,  
20           and

21           c. the drug dispensed by the pharmacist or pharmacy  
22           shares all but the last two digits of the National  
23           Drug Code of the drug reflected on the supplier  
24           invoice.



1        3. An entity conducting an audit shall accept as evidence,  
2 subject to validation, to support the validity of a pharmacy claim  
3 related to a dispensed drug:

- 4            a. redacted copies of supplier invoices in the
- 5                      pharmacist's or pharmacy's possession, or
- 6            b. invoices and any supporting documents from any
- 7                      supplier as authorized by federal or state law to
- 8                      transfer ownership of the drug acquired by the
- 9                      pharmacist or pharmacy.

10        4. An entity conducting an audit shall provide, no later than  
11 five (5) calendar days after the date of a request by the pharmacist  
12 or pharmacy, all supporting documents the pharmacist's or pharmacy's  
13 purchase suppliers provided to the health benefits plan issuer or  
14 pharmacy benefits manager.

15        C. A pharmacy shall be allowed to provide the pharmacy's  
16 computerized patterned medical records or the records of a hospital,  
17 physician, or other authorized practitioner of the healing arts for  
18 drugs or medicinal supplies written or transmitted by any means of  
19 communication for purposes of supporting the pharmacy record with  
20 respect to orders or refills of a legend or narcotic drug.

21        ~~D. The entity conducting the audit shall not audit more than~~  
22 ~~fifty prescriptions, with specific date of service, per calendar~~  
23 ~~year~~ PBM or its agent shall not exceed an annual limit of one  
24 hundred prescription claims with a specific prescription number and

1 date of fill per calendar year. The annual limit to the number of  
2 prescription claims audited shall be inclusive of all audits by a  
3 PBM or its agent, including any prescription-related documentation  
4 requests from the health insurer, pharmacy benefits manager or any  
5 third-party company conducting audits on behalf of any health  
6 insurer or pharmacy benefits manager during a calendar year.  
7 Notwithstanding the annual limit on the number of prescription  
8 claims per calendar year pursuant to this section, no PBM or its  
9 agent shall exceed more than fifty prescription claims with a  
10 specific prescription number and date of fill on an individual  
11 audit.

12 E. If paper copies of records are requested by the entity  
13 conducting the audit, the entity shall pay twenty-five cents (\$0.25)  
14 per page to cover the costs incurred by the pharmacy. The entity  
15 conducting the audit shall provide the pharmacy with accurate  
16 instructions, including any required form for obtaining  
17 reimbursement for the copied records.

18 F. The entity conducting the audit shall:

19 1. Deliver a preliminary audit findings report to the pharmacy  
20 and the pharmacy's contracting agent within forty-five (45) calendar  
21 days of conducting the audit;

22 2. Allow the pharmacy at least ninety (90) calendar days  
23 following receipt of the preliminary audit findings report in which  
24 to produce documentation to address any discrepancy found during the

1 audit; provided, however, a pharmacy may request an extension, not  
2 to exceed an additional forty-five (45) calendar days;

3 3. Deliver a final audit findings report to the pharmacy and  
4 the pharmacy's contracting agent signed by the auditor within ten  
5 (10) calendar days after receipt of additional documentation  
6 provided by the pharmacy, as provided for in Section 356.3 of this  
7 title;

8 4. Allow the pharmacy to reverse and resubmit claims  
9 electronically within thirty (30) calendar days of receipt of the  
10 final audit report in lieu of the auditing entity recouping  
11 discrepant claim amounts from the pharmacy;

12 5. Not recoup any disputed funds until after final disposition  
13 of the audit findings, including the appeals process as provided for  
14 in Section 356.3 of this title; ~~and~~

15 6. Not accrue interest during the audit and appeal period;

16 7. Ensure that each preliminary audit findings report required  
17 by this section includes:

18 a. specific prescription numbers, fill dates, drug names,  
19 and NDC numbers, and

20 b. the date of receipt of documents from the pharmacy,  
21 the pharmacy's contracting agent, or any other source  
22 associated with the audit.  
23  
24

1       ~~G. Each entity conducting an audit shall provide a copy of the~~  
2 ~~final audit results, and a final audit report upon request, after~~  
3 ~~completion of any review process to the plan sponsor~~

4       In addition to the requirements for a preliminary audit findings  
5 report in this paragraph, the final audit findings report shall  
6 include any additional documentation that was submitted to the  
7 auditing entity;

8       8. Provide the plan sponsor a copy of the final audit results  
9 within thirty (30) calendar days of the final disposition of the  
10 audit; and

11       9. At the request of the plan sponsor, provide a copy of the  
12 final audit findings report within thirty (30) calendar days of the  
13 request.

14       ~~H.~~ G. 1. The full amount of any recoupment on an audit shall  
15 be refunded to the plan sponsor. Except as provided for in  
16 paragraph 2 of this subsection, a charge or assessment for an audit  
17 shall not be based, directly or indirectly, on amounts recouped.

18       2. This subsection does not prevent the entity conducting the  
19 audit from charging or assessing the responsible party, directly or  
20 indirectly, based on amounts recouped if both of the following  
21 conditions are met:

- 22           a. the plan sponsor and the entity conducting the audit  
23               have a contract that explicitly states the percentage  
24               charge or assessment to the plan sponsor, and

1           b.     a commission to an agent or employee of the entity  
2                     conducting the audit is not based, directly or  
3                     indirectly, on amounts recouped.

4       ~~H.~~ H. Unless superseded by state or federal law, auditors shall  
5 only have access to previous audit reports on a particular pharmacy  
6 conducted by the auditing entity for the same pharmacy benefits  
7 manager, health plan or insurer. An auditing vendor contracting  
8 with multiple pharmacy benefits managers or health insurance plans  
9 shall not use audit reports or other information gained from an  
10 audit on a pharmacy to conduct another audit for a different  
11 pharmacy benefits manager or health insurance plan.

12       ~~J. Sections A through I~~

13       I. Paragraph 2 of subsection A of this section through  
14 subsection D of this section, and paragraph 1 through paragraph 7 of  
15 subsection F of this section shall not apply to any audit initiated  
16 based on ~~or that involves~~ suspicion of fraud, willful  
17 misrepresentation, or abuse.

18       ~~K.~~ J. If the Attorney General, after notice and opportunity for  
19 hearing, finds that the entity conducting the audit failed to follow  
20 any of the requirements pursuant to the Pharmacy Audit Integrity  
21 Act, the audit shall be considered null and void. Any monies  
22 recouped from a null and void audit shall be returned to the  
23 affected pharmacy within fourteen (14) calendar days. Any violation  
24

1 of this section by a pharmacy benefits manager or auditing entity  
2 shall be deemed a violation of the Pharmacy Audit Integrity Act.

3 SECTION 3. AMENDATORY 59 O.S. 2021, Section 356.3, as  
4 amended by Section 3, Chapter 332, O.S.L. 2024 (59 O.S. Supp. 2024,  
5 Section 356.3), is amended to read as follows:

6 Section 356.3. A. Each entity conducting an audit shall  
7 establish a written appeals process under which a pharmacy may  
8 appeal an unfavorable preliminary audit report and/or final audit  
9 report to the entity.

10 B. Following an appeal, if the entity finds that an unfavorable  
11 audit report or any portion thereof is unsubstantiated, the entity  
12 shall dismiss the audit report or the unsubstantiated portion of the  
13 audit report without any further action.

14 C. Any final audit report, following the final audit appeal  
15 period, with a finding of fraud or willful misrepresentation shall  
16 be referred to the district attorney having proper jurisdiction or  
17 the Attorney General for prosecution upon completion of the appeals  
18 process. If a finding of fraud or willful misrepresentation is  
19 referred to a district attorney under this subsection, the auditing  
20 entity shall notify the Attorney General as to whom the referral was  
21 made and the date the referral was made.

22 D. For any audit initiated based on ~~or that involves~~ suspicion  
23 of fraud, willful misrepresentation, or abuse, the auditing entity  
24 shall provide, in writing, at the time of the audit, a clear and

1 conspicuous declaration to the pharmacy being audited that the audit  
2 is being conducted under suspicion of fraud, willful  
3 misrepresentation, or abuse and a statement of facts that supports  
4 the reasonable suspicion. The entity conducting an audit based on  
5 suspicion of fraud, willful misrepresentation, or abuse shall  
6 provide a copy of the clear and conspicuous declaration required by  
7 this subsection to the pharmacy's contracting agent by certified  
8 mail within five (5) business days of notifying the pharmacy of an  
9 audit pursuant to this section.

10 E. The entity conducting an audit based on suspicion of fraud,  
11 willful misrepresentation, or abuse shall:

12 1. Deliver a preliminary findings report to the pharmacy and  
13 the pharmacy's contracting agent within ninety (90) calendar days of  
14 notification of the audit;

15 2. Allow the pharmacy at least ninety (90) calendar days  
16 following the receipt of the preliminary audit findings report in  
17 which to produce documentation to address any discrepancy found  
18 during the audit. A pharmacy may request an extension, not to  
19 exceed an additional forty-five (45) calendar days;

20 3. Deliver a final audit findings report to the pharmacy and  
21 the pharmacy's contracting agent signed by the auditor within thirty  
22 (30) calendar days after receipt of additional documentation  
23 provided by the pharmacy;  
24

1       4. Allow the pharmacy to reverse and resubmit claims  
2 electronically within thirty (30) calendar days of receipt of the  
3 final audit report in lieu of the auditing entity recouping  
4 discrepant claim amounts from the pharmacy;

5       5. Not recoup any disputed funds until after the final  
6 disposition of the audit findings, including the appeals process  
7 pursuant to this section;

8       6. Not accrue interest during the audit and appeal period;

9       7. Ensure that each preliminary audit findings report submitted  
10 pursuant to this section includes:

11           a. specific prescription numbers, fill dates, drug names,  
12           and NDC numbers, and

13           b. the date of receipt of documents from the pharmacy,  
14           the pharmacy's contracting agent, or any other source  
15           associated with the audit;

16       8. Ensure that each final audit findings report includes any  
17 additional documentation that was submitted to the auditing entity;

18       9. Provide the plan sponsor a copy of the final audit results  
19 within thirty (30) calendar days of the final disposition of the  
20 audit; and

21       10. At the request of the plan sponsor, provide a copy of the  
22 final audit report within thirty (30) calendar days of the request.



1        F. Any entity conducting an audit that is based on ~~or involves~~  
2        suspicion of fraud, willful misrepresentation, or abuse shall  
3        provide to the Office of the Attorney General:

4            1. Notice at least two (2) calendar days prior to beginning  
5        performance of an audit pursuant to this section;

6            2. A preliminary report within ~~thirty (30)~~ calendar days of  
7        ~~performing the audit~~ five (5) business days of providing a copy of  
8        the preliminary report to the pharmacy and the pharmacy's  
9        contracting agent pursuant to this section. The auditing entity may  
10       request an extension from the Attorney General, not to exceed an  
11       additional ninety (90) calendar days; and

12           3. A final report within ~~thirty (30)~~ ten (10) calendar days  
13       following the closure of the final appeal period for an audit  
14       performed pursuant to this section.

15           a.    The final report for the Office of the Attorney  
16                  General shall include the name of each plan sponsor  
17                  whose claims were included in the audit recover, the  
18                  amount of funds recouped on behalf of the plan, the  
19                  date the plan sponsor was notified of the recoupment,  
20                  the date the plan sponsor was paid any recoupment, and  
21                  the name and contact information for the  
22                  representative of the plan sponsor who was notified of  
23                  the recoupment at issue in an audit pursuant to this  
24                  section.

1           **b.**    The auditing entity may request an extension from the  
2                    Attorney General, not to exceed an additional ten (10)  
3                    calendar days.

4           ~~F.~~ **G.**   The Attorney General, authorized employees, and examiners  
5 shall have access to any pharmacy benefits manager's files and  
6 records that may relate to ~~an~~ any audit including, but not limited  
7 to, an audit that is based on ~~or involves~~ suspicion of fraud,  
8 willful misrepresentation, or abuse.

9           ~~G.~~ **H.**   The Attorney General may levy a civil or administrative  
10 fine ~~of~~ not less than One Hundred Dollars (\$100.00) and not greater  
11 than Ten Thousand Dollars (\$10,000.00) for each violation of this  
12 section and assess any other penalty or remedy authorized by law.

13           SECTION 4.        AMENDATORY        59 O.S. 2021, Section 356.4, is  
14 amended to read as follows:

15           Section 356.4.   A.   For the purposes of the Pharmacy Audit  
16 Integrity Act, "extrapolation audit" means an audit of a sample of  
17 prescription drug benefit claims submitted by a pharmacy to the  
18 entity conducting the audit that is then used to estimate audit  
19 results for a larger batch or group of claims not reviewed by the  
20 auditor, including refills not listed in the written notification in  
21 accordance with paragraph 2 of subsection A of Section 356.2 of this  
22 title.

1 B. The entity conducting the audit shall not use the ~~accounting~~  
2 practice of extrapolation in calculating recoupments or penalties  
3 for audits.

4 SECTION 5. NEW LAW A new section of law to be codified  
5 in the Oklahoma Statutes as Section 356.6 of Title 59, unless there  
6 is created a duplication in numbering, reads as follows:

7 A. Notwithstanding any other provision of law, the ability of a  
8 pharmacy benefits manager (PBM) to initiate, continue, or conclude  
9 an audit of a pharmacy shall be tolled for the duration of a  
10 declared disaster and for an additional period of thirty (30)  
11 calendar days following the termination of a declared disaster.

12 Such requirement shall apply only to the pharmacies located  
13 within the geographical boundaries of the county or counties  
14 affected by the declared disaster.

15 B. The provisions of this section shall apply to all PBMs  
16 operating within this state, and to all audits conducted pursuant to  
17 contracts between PBMs and pharmacies.

18 C. This section shall not apply to:

19 1. Audits conducted for suspected fraudulent activity if  
20 documented evidence of such activity exists; or

21 2. Audits required to comply with federal or state law  
22 unrelated to the contractual relationship between a PBM and a  
23 pharmacy.  
24

1 D. Nothing in this section shall be construed to prohibit a  
2 pharmacy from voluntarily agreeing to continue or complete an audit  
3 during the tolling period, provided such agreement is documented in  
4 writing and signed by both parties.

5 E. A PBM may submit a request to the Attorney General to  
6 continue or complete an audit during the tolling period, which the  
7 Attorney General may grant at his or her sole discretion. Any PBM  
8 granted such permission by the Attorney General shall do so pursuant  
9 to the requirements of this act.

10 SECTION 6. AMENDATORY 59 O.S. 2021, Section 357, as  
11 amended by Section 4, Chapter 332, O.S.L. 2024 (59 O.S. Supp. 2024,  
12 Section 357), is amended to read as follows:

13 Section 357. A. As used in Sections 357 through 360 of this  
14 title and Section 8 of this act:

15 1. "Covered entity" means a nonprofit hospital or medical  
16 service organization, for-profit hospital or medical service  
17 organization, insurer, health benefit plan, health maintenance  
18 organization, health program administered by the state in the  
19 capacity of providing health coverage, or an employer, labor union,  
20 or other group of persons that provides health coverage to persons  
21 in this state. This term does not include a health benefit plan  
22 that provides coverage only for accidental injury, specified  
23 disease, hospital indemnity, disability income, or other limited  
24

benefit health insurance policies and contracts that do not include prescription drug coverage;

2. "Covered individual" means a member, participant, enrollee, contract holder or policy holder or beneficiary of a covered entity who is provided health coverage by the covered entity. A covered individual includes any dependent or other person provided health coverage through a policy, contract or plan for a covered individual;

3. "Department" means the Insurance Department;

4. "Maximum allowable cost", "MAC", or "MAC list" means the list of drug products delineating the maximum per-unit reimbursement for multiple-source prescription drugs, medical product, or device;

5. "Multisource drug product reimbursement" (reimbursement) means the total amount paid to a pharmacy inclusive of any reduction in payment to the pharmacy, excluding prescription dispense fees;

6. "Office" means the Office of the Attorney General;

7. "Pharmacy benefits management" means a service provided to covered entities to facilitate the provision of prescription drug benefits to covered individuals within the state, including negotiating pricing and other terms with drug manufacturers and providers. Pharmacy benefits management may include any or all of the following services:

- a. claims processing, retail network management and payment of claims to pharmacies for prescription drugs dispensed to covered individuals,
- b. clinical formulary development and management services, or
- c. rebate contracting and administration;

8. "Pharmacy benefits manager" or "PBM" means a person, business, or other entity that performs pharmacy benefits management. The term shall include any business or entity licensed by the Insurance Department to perform PBM services, or a person or entity acting on behalf of a PBM in a contractual or employment relationship in the performance of pharmacy benefits management for a managed care company, nonprofit hospital, medical service organization, insurance company, third-party payor, or a health program administered by an agency or department of this state;

9. "Plan sponsor" means the employers, insurance companies, unions and health maintenance organizations or any other entity responsible for establishing, maintaining, or administering a health benefit plan on behalf of covered individuals; and

10. "Provider" means a pharmacy licensed by the State Board of Pharmacy, or an agent or representative of a pharmacy, including, but not limited to, the pharmacy's contracting agent, which dispenses prescription drugs or devices to covered individuals.

1 B. Nothing in the definition of pharmacy benefits management or  
2 pharmacy benefits manager in the Patient's Right to Pharmacy Choice  
3 Act, Pharmacy Audit Integrity Act, ~~or~~ Sections 357 through 360 of  
4 this title, or Section 8 of this act shall deem an employer a  
5 ~~"pharmacy benefits manager"~~ pharmacy benefits manager of its own  
6 self-funded health benefit plan, except, to the extent permitted by  
7 applicable law, where the employer, without the utilization of a  
8 third party and unrelated to the employer's own pharmacy:

9 ~~a. negotiates~~

10 1. Negotiates directly with drug manufacturers~~ti~~;

11 ~~b. processes~~

12 2. Processes claims on behalf of its members~~ti~~ or

13 ~~c. manages~~

14 3. Manages its own retail network of pharmacies.

15 SECTION 7. AMENDATORY 59 O.S. 2021, Section 358, as  
16 amended by Section 5, Chapter 332, O.S.L. 2024 (59 O.S. Supp. 2024,  
17 Section 358), is amended to read as follows:

18 Section 358. A. In order to provide pharmacy benefits  
19 management or any of the services included under the definition of  
20 pharmacy benefits management in this state, a pharmacy benefits  
21 manager or any entity acting as one in a contractual or employment  
22 relationship for a covered entity shall first obtain a license from  
23 the Insurance Department, and the Department may charge a fee for  
24 such licensure.

1       B. The Department shall establish, by regulation, licensure  
2 procedures, required disclosures for pharmacy benefits managers  
3 (PBMs) and other rules as may be necessary for carrying out and  
4 enforcing the provisions of this title. The licensure procedures  
5 shall, at a minimum, include the completion of an application form  
6 that shall include the name and address of an agent for service of  
7 process, the payment of a requisite fee, and evidence of the  
8 procurement of a surety bond.

9       C. The Department or the Office of the Attorney General may  
10 subpoena witnesses and information. Its compliance officers may  
11 take and copy records for investigative use and prosecutions.  
12 Nothing in this subsection shall limit the Office of the Attorney  
13 General from using its investigative demand authority to investigate  
14 and prosecute violations of the law.

15       D. The Department may suspend, revoke or refuse to issue or  
16 renew a license for noncompliance with any of the provisions hereby  
17 established or with the rules promulgated by the Department; for  
18 conduct likely to mislead, deceive or defraud the public or the  
19 Department; for unfair or deceptive business practices or for  
20 nonpayment of an application or renewal fee or fine. The Department  
21 may also levy administrative fines for each count of which a PBM has  
22 been convicted in a Department hearing.

23       E. 1. The Office of the Attorney General, after notice and  
24 opportunity for hearing, may instruct the Insurance Commissioner



1 that the PBM's license be censured, suspended, or revoked for  
2 conduct likely to mislead, deceive, or defraud the public or the  
3 State of Oklahoma; or for unfair or deceptive business practices, or  
4 for any violation of the Patient's Right to Pharmacy Choice Act, the  
5 Pharmacy Audit Integrity Act, ~~or~~ Sections 357 through 360 of this  
6 title, or Section 8 of this act. The Office of the Attorney General  
7 may also levy administrative fines for each count of which a PBM has  
8 been convicted following a hearing before the Attorney General. If  
9 the Attorney General makes such instruction, the Commissioner shall  
10 enforce the instructed action within thirty (30) calendar days.

11 2. In addition to or in lieu of any censure, suspension, or  
12 revocation of a license by the Commissioner, the Attorney General  
13 may levy a civil or administrative fine ~~of~~ not less than One Hundred  
14 Dollars (\$100.00) and not greater than Ten Thousand Dollars  
15 (\$10,000.00) for each violation of this subsection and/or assess any  
16 other penalty or remedy authorized by this section. For purposes of  
17 this section, each day a PBM fails to comply with an investigation  
18 or inquiry may be considered a separate violation.

19 F. The Attorney General may promulgate rules to implement the  
20 provisions of Sections 357 through 360 of this title and Section 8  
21 of this act.

22 SECTION 8. AMENDATORY 59 O.S. 2021, Section 360, as  
23 amended by Section 6, Chapter 332, O.S.L. 2024 (59 O.S. Supp. 2024,  
24 Section 360), is amended to read as follows:

1       Section 360. A. The pharmacy benefits manager shall, with  
2       respect to contracts between a pharmacy benefits manager and a  
3       provider, including a pharmacy service administrative organization:

4       1. Include in such contracts the specific sources utilized to  
5       determine the maximum allowable cost (MAC) pricing of the pharmacy,  
6       update MAC pricing at least every seven (7) calendar days, and  
7       establish a process for providers to readily access the MAC list  
8       specific to that provider;

9       2. In order to place a drug on the MAC list, ensure that the  
10      drug is listed as "A" or "B" rated in the most recent version of the  
11      ~~FDA's~~ United States Food and Drug Administration (FDA) Approved Drug  
12      Products with Therapeutic Equivalence Evaluations, also known as the  
13      Orange Book, and the drug is generally available for purchase by  
14      pharmacies in the state from national or regional wholesalers and is  
15      not obsolete;

16      3. Ensure dispensing fees are not included in the calculation  
17      of MAC price reimbursement to pharmacy providers;

18      4. Provide a reasonable administration appeals procedure to  
19      allow a provider, a provider's representative and a pharmacy service  
20      administrative organization to contest reimbursement amounts within  
21      fourteen (14) calendar days of the final adjusted payment date. The  
22      pharmacy benefits manager shall not prevent the pharmacy or the  
23      pharmacy service administrative organization from filing  
24      reimbursement appeals in an electronic batch format. The pharmacy

benefits manager must respond to a provider, a provider's representative and a pharmacy service administrative organization who have contested a reimbursement amount through this procedure within ten (10) calendar days. The pharmacy benefits manager must respond in an electronic batch format to reimbursement appeals filed in an electronic batch format. The pharmacy benefits manager shall not require a pharmacy or pharmacy services administrative organization to log into a system to upload individual claim appeals or to download individual appeal responses. If a price update is warranted, the pharmacy benefits manager shall make the change in the reimbursement amount, permit the dispensing pharmacy to reverse and rebill the claim in question, and make the reimbursement amount change retroactive and effective for all contracted providers; ~~and~~

5. If a below-cost reimbursement appeal is denied, the PBM shall provide the reason for the denial, including the National Drug Code (NDC) number from, and the name of, the specific national or regional wholesalers doing business in this state where the drug is currently in stock and available for purchase by the dispensing pharmacy at a price below the PBM's reimbursement price. The PBM shall include documented proof from the specific national or regional wholesalers doing business in this state showing that the drug is currently in stock and available for purchase by the dispensing pharmacy at a price below the PBM's reimbursement price. If the NDC number provided by the pharmacy benefits manager is not

1 available below the acquisition cost obtained from the  
2 pharmaceutical wholesaler from whom the dispensing pharmacy  
3 purchases the majority of the prescription drugs that are dispensed,  
4 the pharmacy benefits manager shall immediately adjust the  
5 reimbursement amount, permit the dispensing pharmacy to reverse and  
6 rebill the claim in question, and make the reimbursement amount  
7 adjustment retroactive and effective for all contracted providers;

8 6. Any appeal that results in an increase in the reimbursement  
9 from the PBM that continues to be below the pharmacy's acquisition  
10 cost shall be considered a denial under this section. Any denial of  
11 an appeal shall follow the requirements of paragraph 5 of this  
12 subsection; and

13 7. The PBM shall not require a pharmacy to collect additional  
14 monies following a successful below-cost reimbursement appeal from  
15 any person or entity other than the PBM who adjudicated the drug  
16 claim, including the patient or plan sponsor.

17 B. The reimbursement appeal requirements in this section shall  
18 apply to all drugs, medical products, or devices reimbursed  
19 according to any payment methodology, including, but not limited to:

- 20 1. Average acquisition cost, including the National Average  
21 Drug Acquisition Cost;  
22 2. Average manufacturer price;  
23 3. Average wholesale price;  
24 4. Brand effective rate or generic effective rate;

1       5. Discount indexing;

2       6. Federal upper limits;

3       7. Wholesale acquisition cost; and

4       8. Any other term that a pharmacy benefits manager or an  
5 insurer of a health benefit plan may use to establish reimbursement  
6 rates to a pharmacist or pharmacy for pharmacist services.

7       C. The pharmacy benefits manager shall not place a drug on a  
8 MAC list, unless there are at least two therapeutically equivalent,  
9 multiple-source drugs, generally available for purchase by  
10 dispensing retail pharmacies from national or regional wholesalers.

11       D. In the event that a drug is placed on the FDA Drug Shortages  
12 Database, pharmacy benefits managers shall reimburse claims to  
13 pharmacies at no less than the wholesale acquisition cost for the  
14 specific NDC number being dispensed.

15       E. The pharmacy benefits manager shall not require  
16 accreditation or licensing of providers, or any entity licensed or  
17 regulated by the State Board of Pharmacy, other than by the State  
18 Board of Pharmacy or federal government entity as a condition for  
19 participation as a network provider.

20       F. A pharmacy or pharmacist may decline to provide the  
21 pharmacist clinical or dispensing services to a patient or pharmacy  
22 benefits manager if the pharmacy or pharmacist is to be paid less  
23 than the pharmacy's cost for providing the pharmacist clinical or  
24 dispensing services.

1 G. The pharmacy benefits manager shall provide a dedicated  
2 telephone number, email address and names of the personnel with  
3 decision-making authority regarding MAC appeals and pricing.

4 SECTION 9. NEW LAW A new section of law to be codified  
5 in the Oklahoma Statutes as Section 360.1 of Title 59, unless there  
6 is created a duplication in numbering, reads as follows:

7 A. If a disaster declaration is issued for a county in this  
8 state, the time period for a provider, a provider's representative,  
9 or a pharmacy service administrative organization to file a below-  
10 cost reimbursement appeal pursuant to Section 360 of Title 59 of the  
11 Oklahoma Statutes shall be tolled for the duration of the disaster  
12 declaration.

13 B. Upon the expiration of the disaster declaration, the tolling  
14 of the filing period for below-cost reimbursement appeals shall  
15 continue for an additional thirty (30) calendar days. Afterward,  
16 the time period for filing a below-cost reimbursement appeal, as  
17 otherwise provided under state law, shall resume.

18 C. The tolling provisions of this section shall apply only to  
19 continuing counties included in the declared disaster area and to  
20 below-cost reimbursement appeals arising from claims impacted during  
21 the time period of the declared disaster.

22 D. A pharmacy benefits manager (PBM) shall not deny a below-  
23 cost reimbursement appeal on timeliness if such appeal is filed  
24 during the tolled period provided in this section.

1 E. The Attorney General may promulgate rules to implement the  
2 provisions of this act.

3 SECTION 10. It being immediately necessary for the preservation  
4 of the public peace, health or safety, an emergency is hereby  
5 declared to exist, by reason whereof this act shall take effect and  
6 be in full force from and after its passage and approval.

7  
8 60-1-1843 CAD 3/18/2025 2:27:18 PM  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24